Literature DB >> 23478386

Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis.

Oliver Strobel, Markus W Büchler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23478386     DOI： 10.1038/nrgastro.2013.42

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.

Authors:  Shuang Tang; Gang Huang; Jianjun Liu; Tao Liu; Lyndal Treven; Saoli Song; Chenpeng Zhang; Lingling Pan; Ting Zhang
Journal:  Eur J Radiol       Date:  2009-10-23       Impact factor: 3.528

Review 2.  Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).

Authors:  Katherine Cameron; Sivan Golan; William Simpson; Steven Peti; Sasan Roayaie; Daniel Labow; Lale Kostakoglu
Journal:  Abdom Imaging       Date:  2011-08

3.  FDG-PET/CT findings of autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Kensuke Takum; Hajime Anjiki; Naoto Egawa; Masanao Kurata; Goro Honda; Koji Tsuruta
Journal:  Hepatogastroenterology       Date:  2010 May-Jun

4.  Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen W Behrman; Edgar Ben-Josef; Al B Benson; Ephraim S Casper; Steven J Cohen; Brian Czito; Joshua D I Ellenhorn; William G Hawkins; Joseph Herman; John P Hoffman; Andrew Ko; Srinadh Komanduri; Albert Koong; Wen Wee Ma; Mokenge P Malafa; Nipun B Merchant; Sean J Mulvihill; Peter Muscarella; Eric K Nakakura; Jorge Obando; Martha B Pitman; Aaron R Sasson; Anitra Tally; Sarah P Thayer; Samuel Whiting; Robert A Wolff; Brian M Wolpin; Deborah A Freedman-Cass; Dorothy A Shead
Journal:  J Natl Compr Canc Netw       Date:  2012-06-01       Impact factor: 11.908

Review 5.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.

Authors:  Giorgio Treglia; Paola Castaldi; Guido Rindi; Alessandro Giordano; Vittoria Rufini
Journal:  Endocrine       Date:  2012-02-20       Impact factor: 3.633

Review 6.  PET/CT of cancer patients: part 1, pancreatic neoplasms.

Authors:  Elizabeth H Dibble; Dimitrios Karantanis; Gustavo Mercier; Patrick J Peller; Lisa A Kachnic; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2012-11       Impact factor: 3.959

7.  CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.

Authors:  Werner Hartwig; Oliver Strobel; Ulf Hinz; Stefan Fritz; Thilo Hackert; Constanze Roth; Markus W Büchler; Jens Werner
Journal:  Ann Surg Oncol       Date:  2012-12-18       Impact factor: 5.344

8.  18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma.

Authors:  Ippei Matsumoto; Sachiyo Shirakawa; Makoto Shinzeki; Sadaki Asari; Tadahiro Goto; Tetsuo Ajiki; Takumi Fukumoto; Kazuhiko Kitajima; Yonson Ku
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-22       Impact factor: 11.382

9.  Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  H Friess; J Langhans; M Ebert; H G Beger; J Stollfuss; S N Reske; M W Büchler
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

10.  Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.

Authors:  Hirotada Kittaka; Hidenori Takahashi; Hiroaki Ohigashi; Kunihito Gotoh; Terumasa Yamada; Yasuhiko Tomita; Yoshihisa Hasegawa; Masahiko Yano; Osamu Ishikawa
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352
  10 in total
  17 in total

Review 1.  Diagnosis and management of pancreatic cystic neoplasms.

Authors:  Mathew James Keegan; Bharat Paranandi
Journal:  Frontline Gastroenterol       Date:  2019-03-01

Review 2.  Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Xi Hu; Fan Xia; Jiyoung Lee; Fangyuan Li; Xiaoyang Lu; Xiaozhen Zhuo; Guangjun Nie; Daishun Ling
Journal:  Adv Sci (Weinh)       Date:  2021-02-12       Impact factor: 16.806

Review 3.  Pancreatic cancer: diagnosis and treatments.

Authors:  Hong-Yu Li; Zhong-Min Cui; Jiang Chen; Xiao-Zhong Guo; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-02-14

4.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

Review 5.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

6.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.

Authors:  Yizhen Pang; Long Zhao; Qihang Shang; Tinghua Meng; Liang Zhao; Liuxing Feng; Shuangjia Wang; Ping Guo; Xiurong Wu; Qin Lin; Hua Wu; Weipeng Huang; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

7.  Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions.

Authors:  Katja Steiger; Anna-Melissa Schlitter; Wilko Weichert; Irene Esposito; Hans-Jürgen Wester; Johannes Notni
Journal:  Mol Imaging       Date:  2017-01-01       Impact factor: 4.488

8.  Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.

Authors:  Julia Baguña Torres; James C Knight; Michael J Mosley; Veerle Kersemans; Sofia Koustoulidou; Danny Allen; Paul Kinchesh; Sean Smart; Bart Cornelissen
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

9.  Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.

Authors:  Manuel Röhrich; Patrick Naumann; Frederik L Giesel; Peter L Choyke; Fabian Staudinger; Annika Wefers; Dawn P Liew; Clemens Kratochwil; Hendrik Rathke; Jakob Liermann; Klaus Herfarth; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Matthias Lang; Stefan A Koerber
Journal:  J Nucl Med       Date:  2020-10-23       Impact factor: 10.057

10.  Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.

Authors:  María José Ferri; Marc Saez; Joan Figueras; Esther Fort; Miriam Sabat; Santiago López-Ben; Rafael de Llorens; Rosa Núria Aleixandre; Rosa Peracaula
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.